Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Cramer Thinks Our Favorite Biotech Could Be a Buyout Play

When we first recommended this stock back in early February of last year (and in subsequent follow-on reports), we based our "call" on the fact that the company:

  • Has great science.
  • Is targeting a market with a huge need.
  • And could end up either partnering with a Big Pharma player, or being "taken out" in a lucrative (for you) buyout transaction.

This is one recommendation that's worked out even better than we expected - all because of the three potential catalysts we identified...

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK